A Preliminary Abundance Estimate Of An Atlantic Sturgeon (Acipenser Oxyrinchus Oxyrinchus) Contingent Within An Open Riverine System

Abundance estimates are essential for fisheries management, but estimating the abundance of open populations with low recapture rates has historically been unreliable. However, by using mark-recapture data modulated with survivability parameters obtained from analysis of acoustic telemetry data, more accurate abundance estimates can be made for species that exhibit these characteristics. One such species is the Atlantic sturgeon, for which abundance estimates were designated a research priority following precipitous population declines throughout the 20th century. We addressed this research need in the Saco River Estuary (SRE), a system where the Atlantic sturgeon has been extensively studied using mark-recapture and acoustic telemetry methods since 2009. These data were analyzed using Bayesian analysis of a Lincoln-Peterson estimator, constrained with parameters from a Cormack-Jolly-Seber model, to provide an initial abundance estimate for the system. The resulting estimate indicated that approximately 3 299 (95% Credible Interval: 1 462–6 828) Atlantic sturgeon utilize the SRE yearly, suggesting that the SRE provides critical foraging habitat to a large contingent of the species within the Gulf of Maine. The present study demonstrated the method utilized herein was effective in generating a reasonable estimate of abundance in an open system where recapture events are rare, and therefore may provide a valuable technique for supplying initial estimates of fish abundance in additional systems that display similar characteristics

A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats.

The Neuropeptide S receptor, a Gs/Gq-coupled GPCR expressed in brain regions involved in mediating drug reward, has recently emerged as a candidate therapeutic target in addictive disorders. Here, we describe the in vitro and in vivo pharmacology of a novel, selective and brain penetrant NPSR antagonist with nanomolar affinity for the NPSR, NCGC00185684. In vitro, NCGC00185684 shows biased antagonist properties, and preferentially blocks ERK-phosphorylation over intracellular cAMP or calcium responses to NPS. In vivo, systemic NCGC00185684 blocks alcohol-induced ERK-phosphorylation in the rat central amygdala, a region involved in regulation of alcohol intake. NCGC00185684 also decreases operant alcohol self-administration, and lowers motivation for alcohol reward as measured using progressive ratio responding. These effects are behaviorally specific, in that they are observed at doses that do not influence locomotor activity or reinstatement responding following extinction. Together, these data provide an initial validation of the NPSR as a therapeutic target in alcoholism

A Novel Brain Penetrant NPS Receptor Antagonist, NCGC00185684, Blocks Alcohol-Induced ERK-Phosphorylation in the Central Amygdala and Decreases Operant Alcohol Self-Administration in Rats

The Neuropeptide S receptor, a Gs/Gq-coupled GPCR expressed in brain regions involved in mediating drug reward, has recently emerged as a candidate therapeutic target in addictive disorders. Here, we describe the in vitro and in vivo pharmacology of a novel, selective and brain penetrant NPSR antagonist with nanomolar affinity for the NPSR, NCGC00185684. In vitro, NCGC00185684 shows biased antagonist properties, and preferentially blocks ERK-phosphorylation over intracellular cAMP or calcium responses to NPS. In vivo, systemic NCGC00185684 blocks alcohol-induced ERK-phosphorylation in the rat central amygdala, a region involved in regulation of alcohol intake. NCGC00185684 also decreases operant alcohol self-administration, and lowers motivation for alcohol reward as measured using progressive ratio responding. These effects are behaviorally specific, in that they are observed at doses that do not influence locomotor activity or reinstatement responding following extinction. Together, these data provide an initial validation of the NPSR as a therapeutic target in alcoholism